Insomnia - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2016, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insomnia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 9, 3, 6 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.Insomnia.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
Insomnia Overview 9
Therapeutics Development 10
Pipeline Products for Insomnia - Overview 10
Pipeline Products for Insomnia - Comparative Analysis 11
Insomnia - Therapeutics under Development by Companies 12
Insomnia - Therapeutics under Investigation by Universities/Institutes 14
Insomnia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Insomnia - Products under Development by Companies 18
Insomnia - Products under Investigation by Universities/Institutes 19
Insomnia - Companies Involved in Therapeutics Development 20
Actelion Ltd 20
Alexza Pharmaceuticals, Inc. 21
Eisai Co., Ltd. 22
Evotec AG 23
Grupo Ferrer Internacional, S.A. 24
Heptares Therapeutics Limited 25
Intec Pharma Ltd 26
Intra-Cellular Therapies, Inc. 27
Johnson & Johnson 28
Leading BioSciences, Inc. 29
Merck & Co., Inc. 30
Neurim Pharmaceuticals Ltd 31
Novartis AG 32
Reviva Pharmaceuticals Inc. 33
Shionogi & Co., Ltd. 34
Takeda Pharmaceutical Company Limited 35
Insomnia - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 45
(diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ACT-541468 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
CB-2810 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
DORA-12 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Drug for Insomnia - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
EVT-201 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
HTL-6641 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ITI-007 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
JNJ-42847922 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
JNJ-48816274 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
LASSBio-785 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
LASSBio-786 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
lemborexant - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
lorediplon - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
MK-8133 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
NEO-1940 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
piromelatine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
ramelteon - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
S-117957 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
UCM-765 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
zaleplon - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
zaleplon - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
zolpidem tartrate - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Insomnia - Dormant Projects 85
Insomnia - Discontinued Products 88
Insomnia - Product Development Milestones 89
Featured News & Press Releases 89
Sep 08, 2016: Ergomed Completes Recruitment of Phase IIa Clinical Trial of Lorediplon in Insomnia in Collaboration with co-development Partner Ferrer 89
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia 89
Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202 90
Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 91
Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 91
Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe 92
Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 92
Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 92
Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia 93
Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 94
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 95
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 96
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 97
Jul 26, 2013: Takeda Pharma Receives FDA Approval For Rozerem 98
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 98

Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Number of Products under Development for Insomnia, H2 2016 10
Number of Products under Development for Insomnia - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Insomnia - Pipeline by Actelion Ltd, H2 2016 20
Insomnia - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016 21
Insomnia - Pipeline by Eisai Co., Ltd., H2 2016 22
Insomnia - Pipeline by Evotec AG, H2 2016 23
Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 24
Insomnia - Pipeline by Heptares Therapeutics Limited, H2 2016 25
Insomnia - Pipeline by Intec Pharma Ltd, H2 2016 26
Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 27
Insomnia - Pipeline by Johnson & Johnson, H2 2016 28
Insomnia - Pipeline by Leading BioSciences, Inc., H2 2016 29
Insomnia - Pipeline by Merck & Co., Inc., H2 2016 30
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 31
Insomnia - Pipeline by Novartis AG, H2 2016 32
Insomnia - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 33
Insomnia - Pipeline by Shionogi & Co., Ltd., H2 2016 34
Insomnia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 35
Assessment by Monotherapy Products, H2 2016 36
Assessment by Combination Products, H2 2016 37
Number of Products by Stage and Target, H2 2016 39
Number of Products by Stage and Mechanism of Action, H2 2016 41
Number of Products by Stage and Route of Administration, H2 2016 43
Number of Products by Stage and Molecule Type, H2 2016 44
Insomnia - Dormant Projects, H2 2016 85
Insomnia - Dormant Projects (Contd..1), H2 2016 86
Insomnia - Dormant Projects (Contd..2), H2 2016 87
Insomnia - Discontinued Products, H2 2016 88